These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 38635586

  • 21. Single nucleotide polymorphism in the microRNA-199a binding site of HIF1A gene is associated with pancreatic ductal adenocarcinoma risk and worse clinical outcomes.
    Wang X, Ren H, Zhao T, Ma W, Dong J, Zhang S, Xin W, Yang S, Jia L, Hao J.
    Oncotarget; 2016 Mar 22; 7(12):13717-29. PubMed ID: 26872370
    [Abstract] [Full Text] [Related]

  • 22. The value of a metabolic reprogramming-related gene signature for pancreatic adenocarcinoma prognosis prediction.
    Tan Z, Lei Y, Xu J, Shi S, Hua J, Zhang B, Meng Q, Liu J, Zhang Y, Wei M, Yu X, Liang C.
    Aging (Albany NY); 2020 Nov 20; 12(23):24228-24241. PubMed ID: 33226369
    [Abstract] [Full Text] [Related]

  • 23. Improved predictability of pancreatic ductal adenocarcinoma diagnosis using a blood immune cell biomarker panel developed from bulk mRNA sequencing and single-cell RNA-sequencing.
    Jang SI, Lee HK, Chang EJ, Kim S, Kim SY, Hong IY, Kim JK, Lee HS, Yang J, Cho JH, Lee DK.
    Cancer Immunol Immunother; 2023 Aug 20; 72(8):2757-2768. PubMed ID: 37165046
    [Abstract] [Full Text] [Related]

  • 24. Plasma microRNAs as biomarkers of pancreatic cancer risk in a prospective cohort study.
    Duell EJ, Lujan-Barroso L, Sala N, Deitz McElyea S, Overvad K, Tjonneland A, Olsen A, Weiderpass E, Busund LT, Moi L, Muller D, Vineis P, Aune D, Matullo G, Naccarati A, Panico S, Tagliabue G, Tumino R, Palli D, Kaaks R, Katzke VA, Boeing H, Bueno-de-Mesquita HBA, Peeters PH, Trichopoulou A, Lagiou P, Kotanidou A, Travis RC, Wareham N, Khaw KT, Ramon Quiros J, Rodríguez-Barranco M, Dorronsoro M, Chirlaque MD, Ardanaz E, Severi G, Boutron-Ruault MC, Rebours V, Brennan P, Gunter M, Scelo G, Cote G, Sherman S, Korc M.
    Int J Cancer; 2017 Sep 01; 141(5):905-915. PubMed ID: 28542740
    [Abstract] [Full Text] [Related]

  • 25. THBS2/CA19-9 Detecting Pancreatic Ductal Adenocarcinoma at Diagnosis Underperforms in Prediagnostic Detection: Implications for Biomarker Advancement.
    Udgata S, Takenaka N, Bamlet WR, Oberg AL, Yee SS, Carpenter EL, Herman D, Kim J, Petersen GM, Zaret KS.
    Cancer Prev Res (Phila); 2021 Feb 01; 14(2):223-232. PubMed ID: 33067248
    [Abstract] [Full Text] [Related]

  • 26. Serum platelet factor 4 is an independent predictor of survival and venous thromboembolism in patients with pancreatic adenocarcinoma.
    Poruk KE, Firpo MA, Huerter LM, Scaife CL, Emerson LL, Boucher KM, Jones KA, Mulvihill SJ.
    Cancer Epidemiol Biomarkers Prev; 2010 Oct 01; 19(10):2605-10. PubMed ID: 20729288
    [Abstract] [Full Text] [Related]

  • 27. Update on the management of pancreatic cancer: surgery is not enough.
    Ansari D, Gustafsson A, Andersson R.
    World J Gastroenterol; 2015 Mar 21; 21(11):3157-65. PubMed ID: 25805920
    [Abstract] [Full Text] [Related]

  • 28. An Exosome-based Transcriptomic Signature for Noninvasive, Early Detection of Patients With Pancreatic Ductal Adenocarcinoma: A Multicenter Cohort Study.
    Nakamura K, Zhu Z, Roy S, Jun E, Han H, Munoz RM, Nishiwada S, Sharma G, Cridebring D, Zenhausern F, Kim S, Roe DJ, Darabi S, Han IW, Evans DB, Yamada S, Demeure MJ, Becerra C, Celinski SA, Borazanci E, Tsai S, Kodera Y, Park JO, Bolton JS, Wang X, Kim SC, Von Hoff D, Goel A.
    Gastroenterology; 2022 Nov 21; 163(5):1252-1266.e2. PubMed ID: 35850192
    [Abstract] [Full Text] [Related]

  • 29. Plasma extracellular vesicle messenger RNA profiling identifies prognostic EV signature for non-invasive risk stratification for survival prediction of patients with pancreatic ductal adenocarcinoma.
    Han Y, Drobisch P, Krüger A, William D, Grützmann K, Böthig L, Polster H, Seifert L, Seifert AM, Distler M, Pecqueux M, Riediger C, Plodeck V, Nebelung H, Weber GF, Pilarsky C, Kahlert U, Hinz U, Roth S, Hackert T, Weitz J, Wong FC, Kahlert C.
    J Hematol Oncol; 2023 Feb 03; 16(1):7. PubMed ID: 36737824
    [Abstract] [Full Text] [Related]

  • 30. A Plasma Biomarker Panel to Identify Surgically Resectable Early-Stage Pancreatic Cancer.
    Balasenthil S, Huang Y, Liu S, Marsh T, Chen J, Stass SA, KuKuruga D, Brand R, Chen N, Frazier ML, Jack Lee J, Srivastava S, Sen S, McNeill Killary A.
    J Natl Cancer Inst; 2017 Aug 01; 109(8):. PubMed ID: 28376184
    [Abstract] [Full Text] [Related]

  • 31. Plasma biomarkers for prediction of early tumor recurrence after resection of pancreatic ductal adenocarcinoma.
    Rittmann MC, Hussung S, Braun LM, Klar RFU, Biesel EA, Fichtner-Feigl S, Fritsch R, Wittel UA, Ruess DA.
    Sci Rep; 2021 Apr 05; 11(1):7499. PubMed ID: 33820913
    [Abstract] [Full Text] [Related]

  • 32. Downregulation of miR-124 predicts poor prognosis in pancreatic ductal adenocarcinoma patients.
    Sun B, Liu X, Gao Y, Li L, Dong Z.
    Br J Biomed Sci; 2016 Oct 05; 73(4):152-157. PubMed ID: 27922430
    [Abstract] [Full Text] [Related]

  • 33. Novel serum protein biomarker panel for early diagnosis of pancreatic cancer.
    Byeon S, McKay MJ, Molloy MP, Gill AJ, Samra JS, Mittal A, Sahni S.
    Int J Cancer; 2024 Jul 15; 155(2):365-371. PubMed ID: 38519999
    [Abstract] [Full Text] [Related]

  • 34. High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients.
    Allenson K, Castillo J, San Lucas FA, Scelo G, Kim DU, Bernard V, Davis G, Kumar T, Katz M, Overman MJ, Foretova L, Fabianova E, Holcatova I, Janout V, Meric-Bernstam F, Gascoyne P, Wistuba I, Varadhachary G, Brennan P, Hanash S, Li D, Maitra A, Alvarez H.
    Ann Oncol; 2017 Apr 01; 28(4):741-747. PubMed ID: 28104621
    [Abstract] [Full Text] [Related]

  • 35. Identification of laminin γ2 as a prognostic and predictive biomarker for determining response to gemcitabine-based therapy in pancreatic ductal adenocarcinoma.
    Okada Y, Nishiwada S, Yamamura K, Sho M, Baba H, Takayama T, Goel A.
    Eur J Cancer; 2021 Mar 01; 146():125-134. PubMed ID: 33607476
    [Abstract] [Full Text] [Related]

  • 36. Development of a Fit-For-Purpose Multi-Marker Panel for Early Diagnosis of Pancreatic Ductal Adenocarcinoma.
    Kim H, Huh S, Park J, Han Y, Ahn KG, Noh Y, Lee SJ, Chu H, Kim SS, Jung HS, Yun WG, Cho YJ, Kwon W, Jang JY, Kang UB.
    Mol Cell Proteomics; 2024 Sep 01; 23(9):100824. PubMed ID: 39097268
    [Abstract] [Full Text] [Related]

  • 37. Do pancreatic cancer and chronic pancreatitis share the same genetic risk factors? A PANcreatic Disease ReseArch (PANDoRA) consortium investigation.
    Campa D, Pastore M, Capurso G, Hackert T, Di Leo M, Izbicki JR, Khaw KT, Gioffreda D, Kupcinskas J, Pasquali C, Macinga P, Kaaks R, Stigliano S, Peeters PH, Key TJ, Talar-Wojnarowska R, Vodicka P, Valente R, Vashist YK, Salvia R, Papaconstantinou I, Shimizu Y, Valsuani C, Zambon CF, Gazouli M, Valantiene I, Niesen W, Mohelnikova-Duchonova B, Hara K, Soucek P, Malecka-Panas E, Bueno-de-Mesquita HBA, Johnson T, Brenner H, Tavano F, Fogar P, Ito H, Sperti C, Butterbach K, Latiano A, Andriulli A, Cavestro GM, Busch ORC, Dijk F, Greenhalf W, Matsuo K, Lombardo C, Strobel O, König AK, Cuk K, Strothmann H, Katzke V, Cantore M, Mambrini A, Oliverius M, Pezzilli R, Landi S, Canzian F.
    Int J Cancer; 2018 Jan 15; 142(2):290-296. PubMed ID: 28913878
    [Abstract] [Full Text] [Related]

  • 38. Elevated serum CA19-9 level is a promising predictor for poor prognosis in patients with resectable pancreatic ductal adenocarcinoma: a pilot study.
    Dong Q, Yang XH, Zhang Y, Jing W, Zheng LQ, Liu YP, Qu XJ.
    World J Surg Oncol; 2014 Jun 02; 12():171. PubMed ID: 24890327
    [Abstract] [Full Text] [Related]

  • 39. Circulating Tumor Cells Expressing Markers of Tumor-Initiating Cells Predict Poor Survival and Cancer Recurrence in Patients with Pancreatic Ductal Adenocarcinoma.
    Poruk KE, Blackford AL, Weiss MJ, Cameron JL, He J, Goggins M, Rasheed ZA, Wolfgang CL, Wood LD.
    Clin Cancer Res; 2017 Jun 01; 23(11):2681-2690. PubMed ID: 27789528
    [Abstract] [Full Text] [Related]

  • 40. Pre-operative Plasma miR-21-5p Is a Sensitive Biomarker and Independent Prognostic Factor in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Surgical Resection.
    Karasek P, Gablo N, Hlavsa J, Kiss I, Vychytilova-Faltejskova P, Hermanova M, Kala Z, Slaby O, Prochazka V.
    Cancer Genomics Proteomics; 2018 Jun 01; 15(4):321-327. PubMed ID: 29976637
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.